OBM Transplantation is an international peer-reviewed Open Access journal, which covers all evidence-based scientific studies related to transplantation, including: transplantation procedures and the maintenance of transplanted tissues or organs; assimilation of grafted tissue and the reconstitution of removed organs or parts of organs; transplantation of heart, lung, kidney, liver, pancreatic islets and bone marrow, etc. Areas related to clinical and experimental transplantation are also of interest.
OBM Transplantation is committed to rapid review and publication, and we aim at serving the international transplant community with high accessibility as well as relevant and high quality content.
We welcome original clinical studies as well as basic science, reviews, short reports/rapid communications, case reports, opinions, technical notes, book reviews as well as letters to the editor.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period).
Islet Cell Transplantation
Submission Deadline: January 15, 2021 (Open) Submit Now
Kenneth L. Brayman, MD, PhD, FACS
Professor of Surgery, Medicine and Biomedical Engineering, Director, Kidney, Pancreas and Islet Transplant Programs, Director, Center for Cellular Therapy and Biologic Theraputics, Department of Surgery, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22908, USA
Research Interests: Transplant immunosuppression; chronic allograft nephropathy; solid organ transplantation in patients with HIV; islet cell transplantation; transplantation tolerance; gene therapy and xenotransplantation; kidney transplantation; pancreas transplantationa
Preeti Chhabra, PhD
Department of Surgery, University of Virginia, Charlottesville, VA 22908, USA
Research Interests: Type 1 diabetes; islet transplantation; inflammatory diseases; transplant immunosuppression; tolerance induction; regenerative medicine and immunoglobulin M therapy
About This Topic
This special issue primarily focuses on beta-cell replacement beyond islets alone, including isolated beta-cells, stem cells, encapsulated cells and xenotransplants. It covers all evidence-based preclinical and clinical research related to islet transplantation, i.e. transplantation procedures; graft survival and prevention of graft dysfunction and failure caused due to immune rejection and the recurrence of autoimmunity; the harmful side-effects of chronic immunosuppression; novel autoimmune and β-cell therapies that restore immune regulation and restore glucose control following islet transplantation; as well as financial and regulatory approval issues. It also invites articles on regeneration of functional insulin-producing beta cells for transplantation; encapsulation or immunoisolation of alternative beta-cell sources; and predictive or prognostic biomarkers that provide surrogate end points to determine the efficacy of islet transplantation. Last but not least, articles in the field of islet xenotransplantation are also invited.
Received: 12 January 2021; Published: 25 March 2021; doi: 10.21926/obm.transplant.2101140
Clinical islet transplantation was first realized over four decades ago at the University of Minnesota. Autologous islet transplantation is now widely recognized as a treatment to prevent diabetes in patients after pancreas excision and is offered at major transplant centers throughout the United States and the world. Type 1 diabetes represent [...]
Received: 02 October 2020; Published: 27 November 2020; doi: 10.21926/obm.transplant.2004127
Islet transplantation is a cellular replacement therapy for severe diabetes mellitus. Although the clinical outcome of islet transplant has been improving, the transplant efficacy of this treatment is not superior to that of pancreatic organ transplantation, a similar transplant therapy. Various factors have been characterized as ‘islet [...]
Received: 20 September 2020; Published: 16 November 2020; doi: 10.21926/obm.transplant.2004125
Clinical islet allotransplantation represents a minimally invasive, efficacious alternative to pancreas transplantation for restoring glycemic control and insulin independence in select patients with type 1 diabetes that is complicated by intractable impaired hypoglycemia awareness and/or severe hypoglycemic events refractory to stabilization [...]
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.